| Drug / Therapy | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer |
| Indication | — |
| Decision Type | Phase 2 |
| Trial Phase | Phase 2 |
| ClinicalTrials.gov | NCT05983276 |
Karyopharm Therapeutics (KPTI) operates in the Oncology sector. The current BiotechSign Score is 44 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 2 date for Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer by Karyopharm Therapeutics (KPTI) is scheduled for August 28, 2030. This is the target date for the FDA to make a decision on this application.
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer is being developed by Karyopharm Therapeutics for the treatment of its target indication. It is currently in Phase 2 clinical trials.
If Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer receives FDA approval, Karyopharm Therapeutics (KPTI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for KPTI on DilutionWatch at dilutionwatch.com/stock/KPTI.html.
You can view the full BiotechSign company profile for Karyopharm Therapeutics (KPTI) at biotechsign.com/app/company/KPTI, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.